Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization.

Authors :: Petrossian G
Ortiz J
Ortiz AC
Koizumi N
Plews R
Source :: Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2022 Dec; Vol. 27 (12), pp. 1006-1007. Date of Electronic Publication: 2022 Oct 17.
Publication Year :: 2022

Subjects :: Humans
Abatacept adverse effects
Graft Rejection prevention & control
Kidney
Allografts
Immunosuppressive Agents adverse effects
Graft Survival
Calcineurin Inhibitors adverse effects
Immunosuppression Therapy

Full Text Access

Tools